Navigation Links
Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline
Date:9/2/2014

DUBLIN, Sept. 2, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' New Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant Irritable Bowel Syndrome (IBS-D).  Actavis' NDA for eluxadoline has been granted priority review status by the FDA.

Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO

"The NDA filing of eluxadoline marks an important step forward for this potential first-in-class treatment, which demonstrates our commitment to helping patients suffering from this debilitating condition," said Paul Covington, MD, Senior Vice President, Clinical Operations & Development at Furiex Pharmaceuticals, a subsidiary of Actavis.  "We are pleased that the FDA has granted eluxadoline a priority review, setting the stage for us to bring this potential  new treatment option to patients promptly." 

The NDA submission for eluxadoline is based on the results of two Phase III clinical studies that met their primary endpoints. The 12- week efficacy portion of the studies demonstrated significant superiority over placebo in the composite endpoint of the simultaneous improvement in both pain and diarrhea at both 75mg and 100mg doses.

Eluxadoline was well-tolerated and the adverse events (reported in greater than 5% of eluxadoline-treated patients and at an incidence greater than placebo) consisted of constipation (7.4% (75 mg) and 8.6% (100 mg) vs 2.5% placebo),  nausea (8.1% (75mg) and 7.5% (100mg) vs 5.1% placebo) and abdominal pain (4.1% (75mg) and 5.0% (100mg) vs 2.7% placebo).  The studies consisted of approximately 2,500 patients. 

Pursuant to pre-NDA discussions with FDA, Actavis is planning to submit an amendment to the NDA with additional data from a study that was ongoing at the time of submission. As a result, it is expected that this will extend the Prescription Drug User Fee Act (PDUFA) date by three months.  The Company expects the PDUFA date to be in Q2 2015.

"There continues to be an unmet need for treatments to manage the chronic symptoms experienced by patients with IBS-D. If approved, eluxadoline could be a promising option for patients who continue to suffer from these symptoms," said Anthony Lembo, MD, Attending Physician, Beth Israel Deaconess Medical Center and Associate Professor of Medicine, Harvard Medical School.

About Eluxadoline Eluxadoline is a novel, orally active investigational compound being developed for the treatment of diarrhea and abdominal pain in men and women with diarrhea predominant irritable bowel syndrome (IBS-D).  Eluxadoline is a combined mu opioid receptor agonist and delta opioid receptor antagonist which acts locally in the gastrointestinal tract and has low systemic absorption and bioavailability.  The dual opioid activity is designed to treat the symptoms of IBS-D while reducing the incidence of constipation that can occur with unopposed mu opioid receptor agonists.

About IBS-DIBS-D is a functional bowel disorder characterized by chronic abdominal pain and frequent diarrhea, which affects approximately 15 million patients in the U.S.  Although the exact cause of IBS-D is not known, symptoms are thought to result from a disturbance in the way the gastrointestinal track and nervous system interact.

IBS-D can be debilitating and there are limited therapeutic options for managing the chronic symptoms. IBS-D is associated with economic burden in direct medical costs and indirect social costs such as absenteeism and lost productivity, along with decreased quality of life.

About ActavisActavis plc (NYSE: ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit Actavis' website at www.actavis.com.

Actavis Cautionary Statement Regarding Forward-Looking Statements Statements contained in this communication that refer to Actavis' estimated or anticipated future results, including estimated synergies, or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this communication. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; market acceptance of and continued demand for Actavis' products; difficulties or delays in manufacturing; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis plc's Annual Report on Form 10-K for the year ended December 31, 2013, Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and from time to time in Actavis' other investor communications. Except as expressly required by law, Actavis disclaims any intent or obligation to update or revise these forward-looking statements.CONTACTS: Investors:Lisa DeFrancesco(862) 261-7152Media: Charlie Mayr(862) 261-8030David Belian(862) 261-8141


'/>"/>
SOURCE Actavis plc
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
10. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
11. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in ... ways they remain in the eye of the beholder, according to experts who offered ... The American Journal of Managed Care. For the full issue, click here . ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):